Although PARPi therapy has been demonstrated to efficiently sensitize BRCA1/2 mutation-associated cancers and improve survival in patients, not all patients respond to therapy and some patients developed drug resistance after initial favorable response [138,139]. The gene discussed is BRCA1; the disease is cancer.